Treatment-resistant Pruritus Associated With Atopic Dermatitis
Immunology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Vanda PharmaceuticalsVLY-686
Clinical Trials (1)
Total enrollment: 69 patients across 1 trials
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Start: Dec 2013Est. completion: Feb 201569 patients
Phase 2Completed
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
12h ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
12h ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
Yesterday
Supply Chain and Procurement Controller
Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space